What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Immune system
Jeffrey S. Weber spends much of his time researching Melanoma, Internal medicine, Ipilimumab, Surgery and Immunology.
His studies in Melanoma integrate themes in fields like Intention-to-treat analysis, Blockade, Hazard ratio, Interleukin 2 and Surrogate endpoint.
Internal medicine is often connected to Oncology in his work.
His Ipilimumab study combines topics in areas such as Adjuvant, Adverse effect and Clinical trial.
His biological study spans a wide range of topics, including Cancer, Chemotherapy and Talimogene laherparepvec.
His work carried out in the field of Surgery brings together such families of science as Gastroenterology, Placebo and Nivolumab.
His most cited work include:
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria (2277 citations)
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. (1630 citations)
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial (1256 citations)
What are the main themes of his work throughout his whole career to date?
Jeffrey S. Weber mainly investigates Melanoma, Internal medicine, Oncology, Cancer research and Ipilimumab.
Jeffrey S. Weber combines subjects such as Immunology, Cancer, Immune system, Immunotherapy and Gastroenterology with his study of Melanoma.
The Nivolumab, Adverse effect and Clinical trial research Jeffrey S. Weber does as part of his general Internal medicine study is frequently linked to other disciplines of science, such as In patient, therefore creating a link between diverse domains of science.
His Oncology study incorporates themes from Pembrolizumab, Regimen, Advanced melanoma and Immune checkpoint inhibitors.
His work on Metastatic melanoma as part of general Cancer research research is often related to HDAC6, thus linking different fields of science.
Jeffrey S. Weber focuses mostly in the field of Ipilimumab, narrowing it down to matters related to Adjuvant therapy and, in some cases, Hazard ratio.
He most often published in these fields:
- Melanoma (54.15%)
- Internal medicine (48.31%)
- Oncology (38.46%)
What were the highlights of his more recent work (between 2017-2021)?
- Melanoma (54.15%)
- Internal medicine (48.31%)
- Oncology (38.46%)
In recent papers he was focusing on the following fields of study:
Jeffrey S. Weber mostly deals with Melanoma, Internal medicine, Oncology, Cancer research and Immunotherapy.
While the research belongs to areas of Melanoma, Jeffrey S. Weber spends his time largely on the problem of Immune checkpoint inhibitors, intersecting his research to questions surrounding Advanced melanoma, Toxicity and Bioinformatics.
Ipilimumab, Cancer, Adverse effect, Adjuvant therapy and Pembrolizumab are the core of his Internal medicine study.
His Ipilimumab study integrates concerns from other disciplines, such as Clinical endpoint, Randomized controlled trial, Placebo, Complete resection and Nivolumab.
His work is dedicated to discovering how Oncology, Clinical trial are connected with Vemurafenib and other disciplines.
His Cancer research research focuses on Immune system and how it relates to Flow cytometry.
Between 2017 and 2021, his most popular works were:
- MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma (162 citations)
- Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. (111 citations)
- Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors (102 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Immune system
The scientist’s investigation covers issues in Melanoma, Internal medicine, Oncology, Cancer research and Immunotherapy.
His Melanoma research is multidisciplinary, incorporating perspectives in Immune checkpoint, Blockade, Chemotherapy, Acute-phase protein and Autoimmunity.
In general Internal medicine, his work in Ipilimumab, Hazard ratio, Adjuvant therapy and Rash is often linked to In patient linking many areas of study.
Jeffrey S. Weber has included themes like Gastroenterology, Nivolumab, Adverse effect and Clinical endpoint in his Ipilimumab study.
His Oncology research incorporates themes from Pembrolizumab, Cancer and Overweight, Obesity.
His Immunotherapy study combines topics from a wide range of disciplines, such as Interleukin 6, CTLA-4, Antigen presentation and Antigen.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
